The company’s anti-retroviral drug, Lamozid, has been pre-qualified and included in a list of about 255 drugs approved for the fund which develops and manufactures drugs against malaria, Aids, tuberculosis, and reproductive health, allafrica.com reported.
Following the certification, Kenya has joined South Africa, Egypt and Zimbabwe that have WHO pre-qualified drugs.
At present, UCL exports its medicines to countries including Sierra Leone, Malawi and Mozambique.